Pharma

Astellas Reports Long-Term Benefits and Strong Safety Profile for IZERVAY™ in Geographic Atrophy

GATHER2 extension data show sustained efficacy and no new safety concerns after 3.5 years of treatment.

Novo Nordisk Pulls Plug on Cell Therapy in $1.3B Restructuring Push

The pharma giant will close its cell therapy unit, cutting 250 jobs and ending work on Type 1 diabetes and Parkinson's programs, as new CEO shifts focus to obesity, diabetes, and liver disease treatments.

Closed Loop Medicine Brings Personalised GLP-1 Dosing to the U.S with WeDosify

UK start-up's new platform promises to cut GLP-1 discontinuation rates by tailoring dose escalation to each patient's response.

Vedanta’s Live Bacteria Cocktail Fails Phase 2 Ulcerative Colitis Trial

While VE202 misses efficacy endpoint, strong safety profile underscores potential of microbiome-based therapies; company doubles down on Phase 3 trial in recurrent C. difficile.

Eli Lilly's Oral GLP-1 Candidate Orforglipron Shows 12% Weight Loss in Pivotal Trial, Eyes Regulatory Filing

Phase 3 data show modest efficacy for Lilly's once-daily oral GLP-1, positioning it as a convenient but less potent rival to injectable obesity drugs.

Antibodies.com Supercharges UK Operations with Move to Larger Cambridge HQ

Antibodies.com has moved to a new, five-times-larger headquarters at Cambridge Technopark to support rapid growth and better serve life science researchers worldwide.